Mortality

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Retrieved on: 
Thursday, December 1, 2022

The Swiss filing was based on the European Union (EU) MAA for Libmeldy, which was approved by the European Commission in December 2020.

Key Points: 
  • The Swiss filing was based on the European Union (EU) MAA for Libmeldy, which was approved by the European Commission in December 2020.
  • Over time, the nervous system is damaged, leading to neurological problems such as motor, behavioral and cognitive regression, severe spasticity and seizures.
  • For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.
  • At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases.

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Retrieved on: 
Wednesday, November 30, 2022

The Agency is currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The Agency is currently planning to hold an advisory committee meeting to discuss this application.
  • SUL-DUR also exhibited a favorable safety profile with statistically significant reduction in nephrotoxicity.
  • Carbapenem-resistant and multidrug-resistant Acinetobacter infections are an urgent and emergent threat due to increasing rates of resistance and few viable treatment options.
  • Our focused and dedicated team looks forward to continuing to work with the FDA throughout the priority review process.

Healthcare Executive Bill Hannah named Partner at ClinIntell

Retrieved on: 
Wednesday, November 30, 2022

TAMPA, Fla., Nov. 30, 2022 /PRNewswire/ -- Bill Hannah has been appointed Partner at ClinIntell, an innovative severity reporting data analytics firm. ClinIntell provides healthcare organizations with unique insights that readily identify severity reporting performance and clinical conditions down to the individual provider.

Key Points: 
  • ClinIntell's unique analytical approach continues to make an impact in healthcare severity reporting as industry leader Bill Hannah joins the firm as Partner.
  • TAMPA, Fla., Nov. 30, 2022 /PRNewswire/ -- Bill Hannah has been appointed Partner at ClinIntell, an innovative severity reporting data analytics firm.
  • ClinIntell provides healthcare organizations with unique insights that readily identify severity reporting performance and clinical conditions down to the individual provider.
  • Bill Hannah is a leader in the healthcare industry with more than 40 years of experience and joins ClinIntell from Guidehouse Consulting, where he served as a Practice Partner.

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

Retrieved on: 
Wednesday, November 30, 2022

We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections.

Key Points: 
  • We congratulate Dr. Ghannoum on receiving this grant and want to express our gratitude for his ongoing commitment to patients suffering from terrible and deadly fungal infections.
  • C. auris has emerged in recent years as a global threat causing serious invasive infections with mortality as high as 60 percent worldwide.
  • The World Health Organization (WHO) recently released its first ever fungal priority pathogens list (FPPL), which includes C. auris in the critical priority group.
  • In addition, late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Shatterproof and the Elevance Health Foundation Partner to Reduce Stigma Around Substance Use Disorder

Retrieved on: 
Wednesday, November 30, 2022

By acknowledging the physical, behavioral and social drivers of health as they relate to substance use disorders, the Elevance Health Foundation along with Shatterproof is positioned to provide meaningful solutions in achieving better health and advancing health equity.

Key Points: 
  • By acknowledging the physical, behavioral and social drivers of health as they relate to substance use disorders, the Elevance Health Foundation along with Shatterproof is positioned to provide meaningful solutions in achieving better health and advancing health equity.
  • The investment from the Elevance Health Foundation is part of a larger commitment of $30 million to substance use disorder.
  • ABOUT THE ELEVANCE HEALTH FOUNDATION:
    Elevance Health Foundation is the philanthropic arm of Elevance Health, Inc.
  • To learn more about Elevance Health Foundation, please visit www.elevancehealth.foundation or follow us @ElevanceFND on Twitter and Elevance Health Foundation on Facebook.

Phoenix Holdings Reports Results for the Third Quarter of 2022 and the Nine Months Ended September 30, 2022; Continues to Improve Performance in Line with Strategic Plan Targets

Retrieved on: 
Wednesday, November 30, 2022

Higher Solvency strengthens the Groups ability to continue investing in attractive financial and strategic opportunities with significant business potential.

Key Points: 
  • Higher Solvency strengthens the Groups ability to continue investing in attractive financial and strategic opportunities with significant business potential.
  • This position, together with the Groups flexible management capabilities and diverse activities, attractively position the Phoenix for continued value creation.
  • The comprehensive income before tax in third quarter of 2022 and the nine months ended September 30, 2022 was NIS 14 million and NIS 73 million, respectively.
  • Phoenix Holdings is a leading Israel-based financial, insurance, and investment group traded on the Tel Aviv Stock Exchange (TASE: PHOE).

Vitamin Angels Partners with Actress and Activist, Tatyana Ali to Advocate for Maternal Health Equity Worldwide

Retrieved on: 
Wednesday, November 30, 2022

Imagine not being able to access the vitamins, minerals and information that are so critical to your family's health?"

Key Points: 
  • Imagine not being able to access the vitamins, minerals and information that are so critical to your family's health?"
  • "In honor of Giving Tuesday, I hope you'll join my family in supporting Vitamin Angels.
  • "We are inspired to be working with Tatyana Ali, whose passion for maternal and child health equity continues to strengthen communities who are underserved," said Howard Schiffer, Vitamin Angels Founder and President/CEO.
  • Founded in 1994, Vitamin Angels is a public health nonprofit working to improve nutrition and health outcomes in low-resource settings worldwide.

Clarametyx Initiates Phase 1 Study of Immune-enabling Antibody Therapy CMTX-101 Against Community-acquired Bacterial Pneumonia

Retrieved on: 
Wednesday, November 30, 2022

(Clarametyx), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced the initiation of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections.

Key Points: 
  • (Clarametyx), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, today announced the initiation of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections.
  • The technology precisely and rapidly destroys the universal underlying structure of bacterial biofilms, which undermines bacterial defenses and enables more effective antibiotic and immune interventions.
  • The company will initiate a Phase 1a safety evaluation in healthy volunteers, evaluating up to four doses of CMTX-101.
  • Clarametyx and its collaborators are separately advancing preclinical assessments of this antibody technology as a possible preventative approach for other bacterial infections.

Healthcare/Medical Simulation Global Market Report 2022: Technology Advancements in Medical Field & Limited Access to Patients During Medical Training to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022

The global healthcare/medical simulation market reached a value of nearly $1,708.12 million in 2021, having grown at a compound annual growth rate (CAGR) of 7.97% since 2016.

Key Points: 
  • The global healthcare/medical simulation market reached a value of nearly $1,708.12 million in 2021, having grown at a compound annual growth rate (CAGR) of 7.97% since 2016.
  • Going forward, product launches and innovations, technology advancements in medical field, limited access to patients during medical training and increasing demand for minimally invasive treatments will drive the growth.
  • Factors that could hinder the growth of the healthcare/medical simulation market in the future include lack of dedicated simulation operations specialists and the expensive cost of medical simulation.
  • 1) By Product And Service: Healthcare Anatomical Models; Web-Based Simulation; Healthcare Simulation Software; Simulation Training Services

Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue

Retrieved on: 
Wednesday, November 30, 2022

GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .

Key Points: 
  • GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels .
  • Presented at their annual UNITE Summit , the Action Plan follows and builds upon the World Heart Federation's Cholesterol Roadmap released in October.
  • The Global Heart Hub aims to implement change in the way unhealthy cholesterol levels are prevented and managed at local levels to reduce ASCVD .
  • The new Action Plan outlines four clear goals to ensure unhealthy cholesterol levels are addressed as a public health priority: build alliances, raise public awareness, activate alliances, and improve high cholesterol detection and management.